Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 24, 2015 10:47 PM ET

Biotechnology

Company Overview of EPIRUS Biopharmaceuticals, Inc.

Company Overview

EPIRUS Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company’s pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment ...

699 Boylston Street

8th Floor

Boston, MA 02116

United States

33 Employees

Phone:

617-600-4313

Key Executives for EPIRUS Biopharmaceuticals, Inc.

Chief Executive Officer, President and Director
Total Annual Compensation: $375.0K
Chief Financial Officer
Total Annual Compensation: $160.4K
Chief Technical Officer
Total Annual Compensation: $280.0K
Compensation as of Fiscal Year 2013.

EPIRUS Biopharmaceuticals, Inc. Key Developments

EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

EPIRUS Biopharmaceuticals, Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $4,000. Loss from operations was $10,156,000 compared to $3,830,000 a year ago. Net loss was $10,400,000 compared to $7,771,000 a year ago. Basic and diluted loss per share was $0.80 compared to $32.79 a year ago. For the year, the company reported revenue of $4,000. Loss from operations was $39,255,000 compared to $14,468,000 a year ago. Net loss was $41,844,000 compared to $20,795,000 a year ago. Basic and diluted loss per share was $6.81 compared to $88.26 a year ago.

EPIRUS Biopharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 24, 2015

EPIRUS Biopharmaceuticals, Inc. announced that they will report Q4, 2014 results on Mar 24, 2015

EPIRUS Biopharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 24, 2015

EPIRUS Biopharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 24, 2015

Similar Private Companies By Industry

Company Name Region
Tissue Engineering, Inc. United States
Floratine BioSciences, Inc. United States
TSG Pharmaceuticals, LLC United States
Sanford Applied Biosciences, LLC United States
Stell United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 30, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIRUS Biopharmaceuticals, Inc., please visit www.epirusbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.